FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286296259> ?p ?o ?g. }

• W4286296259 endingPage "4121" @default.
• W4286296259 startingPage "4121" @default.
• W4286296259 abstract "4121 Background: Treatment options are limited in patients with metastatic NEN. Temozolomide (TEM) alone and in combination with capecitabine is active in NEN and has been shown to have immunomodulatory impact. Here we present the final results for the NEN cohort of a phase 2 trial of combination nivolumab and TEM in patients with advanced NEN along with observed peripheral immune changes. Methods: NCT03728361 is a non-randomized, two-cohort, open-label phase 2 trial of nivolumab and TEM in patients with metastatic NEN and small cell lung cancer. The NEN cohort enrolled patients with tumors of any WHO grade, location, and line of therapy; all patients had evidence of progression prior to study. Prior immunotherapy was not allowed. Treatment consisted of nivolumab 480 mg IV on day 1 and TEM 150 mg/m2 on days 1-5 of a 28-day cycle. The primary objective was efficacy measured as response rate (RR) by RECIST v1.1. Secondary objectives were progression free survival (PFS) and overall survival (OS), by the method of Kaplan–Meier. The translational objective was to analyze peripheral blood mononuclear cells (PBMCs) collected at screening (baseline) and on cycle 1, day 15 (C1D15) via mass cytometry. Results: The RR was 36% (n=10/28, 95% CI: 18.6%-55.9%), including 10 patients (36%) with PR, 16 (57%) with SD, and 2 (7%) with PD (Table). The disease control rate was 93%. Responses occurred across all WHO grades; 44% of patients with tumors with Ki-67 >20% had PR. There was a significant difference in ORR by primary tumor location (bronchial vs pancreas vs other, p=0.004). There was no significant difference in response by Ki-67% (p=0.872), or in patients treated as first line (31%) or beyond (40%, p=0.706). The median PFS was 8.9 months (95% CI: 3.9 – 11.1 months), and median OS was not reached (95% CI: 20.7 – NR months). Two immune related SAE’s occurred: myocarditis and diarrhea in one patient each; gr4 toxicities included neutropenia (10%) and thrombocytopenia (7%). Profiling of PBMCs revealed no correlation of baseline MDSC levels with clinical benefit, however significant changes within the T cell landscape, including a decrease in CD4+ T cells (59.6% ±13.08 vs. 56.5% ±13.01, p=0.001) and increase in CD8+ T cells (27.9% ±13.36 vs. 31.7% ±14.57, p=0.03) were observed. Conclusions: Combination nivolumab and TEM demonstrated promising efficacy in patients with NENs; median OS has not been reached. Clinical trial information: NCT03728361. [Table: see text]" @default.
• W4286296259 created "2022-07-21" @default.
• W4286296259 creator A5004712121 @default.
• W4286296259 creator A5005735075 @default.
• W4286296259 creator A5019613145 @default.
• W4286296259 creator A5024225602 @default.
• W4286296259 creator A5029524605 @default.
• W4286296259 creator A5030653735 @default.
• W4286296259 creator A5035552610 @default.
• W4286296259 creator A5036473043 @default.
• W4286296259 creator A5037127171 @default.
• W4286296259 creator A5040693414 @default.
• W4286296259 creator A5042714463 @default.
• W4286296259 creator A5044303993 @default.
• W4286296259 creator A5051398513 @default.
• W4286296259 creator A5054067683 @default.
• W4286296259 creator A5059445665 @default.
• W4286296259 creator A5060897770 @default.
• W4286296259 creator A5071104992 @default.
• W4286296259 creator A5073968481 @default.
• W4286296259 creator A5077168338 @default.
• W4286296259 creator A5091280788 @default.
• W4286296259 date "2022-06-01" @default.
• W4286296259 modified "2023-09-27" @default.
• W4286296259 title "Efficacy of nivolumab and temozolomide in advanced neuroendocrine neoplasms (NENs) in a phase 2 clinical trial." @default.
• W4286296259 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.4121" @default.
• W4286296259 hasPublicationYear "2022" @default.
• W4286296259 type Work @default.
• W4286296259 citedByCount "1" @default.
• W4286296259 countsByYear W42862962592023 @default.
• W4286296259 crossrefType "journal-article" @default.
• W4286296259 hasAuthorship W4286296259A5004712121 @default.
• W4286296259 hasAuthorship W4286296259A5005735075 @default.
• W4286296259 hasAuthorship W4286296259A5019613145 @default.
• W4286296259 hasAuthorship W4286296259A5024225602 @default.
• W4286296259 hasAuthorship W4286296259A5029524605 @default.
• W4286296259 hasAuthorship W4286296259A5030653735 @default.
• W4286296259 hasAuthorship W4286296259A5035552610 @default.
• W4286296259 hasAuthorship W4286296259A5036473043 @default.
• W4286296259 hasAuthorship W4286296259A5037127171 @default.
• W4286296259 hasAuthorship W4286296259A5040693414 @default.
• W4286296259 hasAuthorship W4286296259A5042714463 @default.
• W4286296259 hasAuthorship W4286296259A5044303993 @default.
• W4286296259 hasAuthorship W4286296259A5051398513 @default.
• W4286296259 hasAuthorship W4286296259A5054067683 @default.
• W4286296259 hasAuthorship W4286296259A5059445665 @default.
• W4286296259 hasAuthorship W4286296259A5060897770 @default.
• W4286296259 hasAuthorship W4286296259A5071104992 @default.
• W4286296259 hasAuthorship W4286296259A5073968481 @default.
• W4286296259 hasAuthorship W4286296259A5077168338 @default.
• W4286296259 hasAuthorship W4286296259A5091280788 @default.
• W4286296259 hasConcept C121608353 @default.
• W4286296259 hasConcept C126322002 @default.
• W4286296259 hasConcept C143998085 @default.
• W4286296259 hasConcept C2776694085 @default.
• W4286296259 hasConcept C2777389519 @default.
• W4286296259 hasConcept C2777701055 @default.
• W4286296259 hasConcept C2777909004 @default.
• W4286296259 hasConcept C2778822529 @default.
• W4286296259 hasConcept C2779984678 @default.
• W4286296259 hasConcept C2780030458 @default.
• W4286296259 hasConcept C2780739268 @default.
• W4286296259 hasConcept C2781433595 @default.
• W4286296259 hasConcept C31760486 @default.
• W4286296259 hasConcept C526805850 @default.
• W4286296259 hasConcept C535046627 @default.
• W4286296259 hasConcept C71924100 @default.
• W4286296259 hasConcept C72563966 @default.
• W4286296259 hasConceptScore W4286296259C121608353 @default.
• W4286296259 hasConceptScore W4286296259C126322002 @default.
• W4286296259 hasConceptScore W4286296259C143998085 @default.
• W4286296259 hasConceptScore W4286296259C2776694085 @default.
• W4286296259 hasConceptScore W4286296259C2777389519 @default.
• W4286296259 hasConceptScore W4286296259C2777701055 @default.
• W4286296259 hasConceptScore W4286296259C2777909004 @default.
• W4286296259 hasConceptScore W4286296259C2778822529 @default.
• W4286296259 hasConceptScore W4286296259C2779984678 @default.
• W4286296259 hasConceptScore W4286296259C2780030458 @default.
• W4286296259 hasConceptScore W4286296259C2780739268 @default.
• W4286296259 hasConceptScore W4286296259C2781433595 @default.
• W4286296259 hasConceptScore W4286296259C31760486 @default.
• W4286296259 hasConceptScore W4286296259C526805850 @default.
• W4286296259 hasConceptScore W4286296259C535046627 @default.
• W4286296259 hasConceptScore W4286296259C71924100 @default.
• W4286296259 hasConceptScore W4286296259C72563966 @default.
• W4286296259 hasIssue "16_suppl" @default.
• W4286296259 hasLocation W42862962591 @default.
• W4286296259 hasOpenAccess W4286296259 @default.
• W4286296259 hasPrimaryLocation W42862962591 @default.
• W4286296259 hasRelatedWork W2936810997 @default.
• W4286296259 hasRelatedWork W2947947780 @default.
• W4286296259 hasRelatedWork W2954924806 @default.
• W4286296259 hasRelatedWork W2990328489 @default.
• W4286296259 hasRelatedWork W3099429605 @default.
• W4286296259 hasRelatedWork W3120622126 @default.
• W4286296259 hasRelatedWork W4242192132 @default.
• W4286296259 hasRelatedWork W4281619570 @default.
• W4286296259 hasRelatedWork W4283751238 @default.

• next